Metronidazole and Peripheral Neuropathy: A Report of Two Cases of (Unusual) Side Effects

Stefano Gussago1,2, Cristiana Poroli Bastone3, Diana Celio1

  • 1General Surgery, Ospedale Regionale di Locarno, Ente Ospedaliero Cantonale, Locarno, CHE.

Cureus
|December 5, 2022
PubMed

Insights

Metronidazole, an antibiotic for anaerobic and protozoan infections, can cause peripheral neuropathy. Prolonged use or high doses may increase this neurological risk, though symptoms often improve after discontinuing the drug.

Area of Science:

  • Neurology
  • Infectious Diseases
  • Pharmacology

Background:

  • Metronidazole is a widely used antibiotic for anaerobic and protozoan infections.
  • Common side effects include gastrointestinal issues, dysgeusia, headaches, and alcohol intolerance.
  • Peripheral neuropathy is a less common but documented adverse effect.

Observation:

  • Two cases of peripheral neuropathy are presented in patients treated with metronidazole.
  • A 69-year-old woman received 55g for diverticular disease; a 52-year-old male received 168g for hepatic abscesses.
  • Neuropathy onset occurred after prolonged treatment or high cumulative doses, with other causes excluded.

Findings:

  • Peripheral neuropathy developed in both patients during or after metronidazole therapy.
  • Symptoms showed varying degrees of improvement upon drug withdrawal.
  • Literature suggests prolonged therapy regimens (over 4 weeks or >42g cumulative dose) are associated with increased risk.

Implications:

  • Clinicians should be vigilant for neurological side effects, particularly peripheral neuropathy, with metronidazole use.
  • Awareness of this risk is crucial, especially in patients undergoing prolonged treatment.
  • Early detection and drug discontinuation can lead to symptom improvement, highlighting the importance of monitoring treatment duration and dosage.

Related Concept Videos

Local Anesthetics: Adverse Effects01:12

Local Anesthetics: Adverse Effects

While local anesthetics are generally safe and well-tolerated, they can occasionally cause adverse effects that vary in severity. Local anesthetics can induce toxicity at two distinct levels. They can either produce local effects through direct contact with the neural elements or be absorbed into the bloodstream from the injection site, leading to systemic effects.
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
480
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
293
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
242
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
407
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
617
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
192